Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia
Ángel Alberto García-Peña; Mariana Pineda-Posada; Carol Páez-Canro; César Cruz; Daniel Samacá-Samacá;
Clin Investig Arterioscler. 2023;35:280-9
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study
Agustín Blanco Echevarría; Juan De Dios García Díaz; Assumpta Caixas; Núria Plana Gil; Miguel Ángel Rico Corral; Ian Bridges; Nafeesa Dhalwani; Sònia Gatell Menchen; Kausik K. Ray;
Clin Investig Arterioscler. 2023;35:263-71
Analysis of the prescription process of PCSK9 inhibitors in the cardiology departments of Spanish hospitals and optimization proposal. The IKIGAI study
Vivencio Barrios; Carlos Escobar; Vicente Arrarte; Marisol Bravo; Alfredo del Campo; Rafael Hidalgo; Lluís Recasens; Ángel Cequier;
Clin Investig Arterioscler. 2021;33:296-305